Intensive Chemotherapy Regimen clinical trials

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

This study looks at adding a new medicine, revumenib, to standard chemotherapy for people with a specific type of newly diagnosed acute myeloid leukaemia (AML) with a particular gene change (NPM1 mutation). It aims to see if this combination works better and is safe.